Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Leerink Partners

Equities research analysts at Leerink Partners initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) in a report issued on Monday, Briefing.com reports. The firm set an “outperform” rating and a $228.00 price target on the stock. Leerink Partners‘s price target would suggest a potential upside of 49.53% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the stock. Chardan Capital restated a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, October 28th. HC Wainwright started coverage on shares of Palvella Therapeutics in a research note on Friday, November 6th. They set a “strong-buy” rating on the stock. William Blair began coverage on shares of Palvella Therapeutics in a research report on Friday, October 16th. They set an “outperform” rating for the company. Canaccord Genuity Group lifted their price objective on shares of Palvella Therapeutics from $232.00 to $243.00 and gave the stock a “buy” rating in a research note on Monday, November 9th. Finally, Oppenheimer boosted their target price on shares of Palvella Therapeutics from $210.00 to $232.00 and gave the stock an “outperform” rating in a report on Friday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $214.86.

View Our Latest Research Report on Palvella Therapeutics

Palvella Therapeutics Price Performance

NASDAQ:PVLA opened at $152.48 on Monday. Palvella Therapeutics has a 1 year low of $72.22 and a 1 year high of $179.95. The stock’s 50 day simple moving average is $143.56 and its two-hundred day simple moving average is $129.97. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -27.72 and a beta of -0.21.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.78) by $0.08. As a group, analysts anticipate that Palvella Therapeutics will post -6.29 EPS for the current year.

Insider Buying and Selling

In other news, Director Christopher Kiritsy sold 313 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the completion of the transaction, the director owned 250 shares in the company, valued at approximately $39,250. The trade was a 55.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeffrey S. Martini sold 6,250 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $166.98, for a total value of $1,043,625.00. Following the transaction, the insider directly owned 4,266 shares in the company, valued at approximately $712,336.68. This represents a 59.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,306 shares of company stock valued at $9,800,571 over the last quarter. Company insiders own 17.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP boosted its stake in Palvella Therapeutics by 11,463.8% during the third quarter. Marshall Wace LLP now owns 329,799 shares of the company’s stock worth $45,489,000 after buying an additional 326,947 shares during the period. Voya Investment Management LLC raised its stake in shares of Palvella Therapeutics by 2.8% in the third quarter. Voya Investment Management LLC now owns 5,878 shares of the company’s stock valued at $811,000 after acquiring an additional 162 shares during the period. Royce & Associates LP raised its stake in shares of Palvella Therapeutics by 24.7% in the third quarter. Royce & Associates LP now owns 50,509 shares of the company’s stock valued at $6,967,000 after acquiring an additional 10,000 shares during the period. ACT Capital Partners L.P. purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at $3,103,000. Finally, William Blair Investment Management LLC bought a new stake in shares of Palvella Therapeutics in the 3rd quarter worth about $26,906,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

(Get Free Report)

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Read More

Analyst Recommendations for Palvella Therapeutics (NASDAQ:PVLA)

Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.